Drug successfully targets cancers with tumor-specific gene mutations

(Nemours) Pediatric and adult cancers with one of three fusion genes responds well to a new drug, larotrectinib, according to a study published today in the New England Journal of Medicine. The drug is designed to target a specific tumor gene mutation known as tropomyosin receptor kinases (TRK) that can occur in various tumor types.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news